2016 editions
- December 2016
Joao Incio on mechanisms to explain why obesity promotes cancer. - November 2016
Mike Stratton on how mutational changes in a cancer genome can point to the cause of the cancer. - October 2016
Ruth Muschel on a new target for treatments for colorectal cancer. - September 2016
Freddie Hamdy on the effectiveness of treatments for prostate cancer. - August 2016
Moshe Oren discusses the effects of the microenvironment on cancer cells. - July 2016
Richard Gilbertson on the 'bad luck hypothesis' for the cause of cancer. - June 2016
Key advances in clinical trials. - May 2016
Mark Lemmon on the underlying biochemistry of cancer. - April 2016
Roger Stupp on using alternating electric fields as treatment. - March 2016
Charlotte Vrinten on public perception of deaths from cancer. - February 2016
Guillermo Garcia-Manero on myelodysplastic syndromes (MDS). - December 2015/January 2016
Nazneen Rahman on germline genetic screening in ovarian cancer.
EJC News Focus – May 2016
Loading EJC News Focus video
Making sense of moving targets
Cancer genomics is providing a plethora of targets for anti-tumour therapies but resistance mutations are a major on-going problem adding levels of complexity that can be hard to unravel.
At the recent Oncology at the Limits meeting in London, Mark Lemmon of Yale School of Medicine told Jim McGuigan there should be a renewed focus on the underlying biochemistry of the system to understand how best to direct new therapy.